Biotechnology Future Medicine Regulation In Russia.

1. Introduction

Future medicine refers to the application of advanced biotechnology, genetic engineering, molecular biology, artificial intelligence, regenerative medicine and other emerging scientific technologies to prevent, diagnose and treat human diseases.

In Russia, future medicine is not governed by one comprehensive statute. Instead, it is regulated through a combination of federal legislation, government resolutions, Ministry of Health regulations, clinical research requirements, licensing rules, ethical safeguards and data-protection legislation.

The principal areas include:

Gene therapy and genome editing.

Stem-cell research and regenerative medicine.

Biomedical cellular products.

Personalised and precision medicine.

Genetic testing and predictive genomics.

Tissue engineering and artificial organs.

Biopharmaceuticals and advanced biological medicines.

Artificial intelligence in medical diagnosis and treatment.

Clinical trials involving emerging technologies.

Biobanks and human biological materials.

The Russian regulatory approach seeks to balance three objectives:

Promoting scientific and technological development.

Protecting patients against unsafe experimental treatments.

Maintaining governmental supervision over medical products, genetic information and biomedical research.

An important feature of Russian law is that different future-medicine technologies may fall under different legal regimes. For example, a cellular therapeutic product may be governed by Federal Law No. 180-FZ, while a genetically engineered medicinal product may fall under Federal Law No. 61-FZ.

2. Constitutional foundation of future medicine regulation

The Constitution of the Russian Federation provides the fundamental legal framework for biotechnology and future medicine.

A. Article 20 – Right to life

Article 20 protects the right to life.

Its relevance includes:

Protection against dangerous experimental medical interventions.

Prevention of unlawful biomedical experimentation.

Regulation of potentially harmful genetic and cellular treatments.

Protection of human dignity in advanced medical research.

Future medicine must not expose individuals to unjustified risks merely because a technology is scientifically innovative.

B. Article 21 – Protection of human dignity

Article 21 provides that human dignity is protected by the state.

This is relevant to:

Human embryo research.

Stem-cell research.

Genetic modification.

Human biological materials.

Reproductive biotechnology.

Experimental cellular therapies.

Medical research must respect the dignity and bodily integrity of research participants.

C. Article 41 – Right to health protection

Article 41 guarantees the right to health protection and medical assistance.

It provides an important constitutional basis for:

Access to innovative medical treatment.

State regulation of healthcare.

Medical research and technological development.

Quality and safety requirements.

Government responsibility for public health.

Legal significance: Constitutional rights operate as the foundation for interpreting federal legislation governing emerging medical technologies.

3. Principal legislation governing future medicine

Russia does not have a single Future Medicine Act. The following legislation forms the central regulatory structure.

LegislationRegulatory subject
Federal Law No. 323-FZ of 2011General healthcare and patient rights
Federal Law No. 61-FZ of 2010Medicinal products and pharmaceutical regulation
Federal Law No. 180-FZ of 2016Biomedical cellular products
Federal Law No. 86-FZ of 1996Genetically engineered activities and genetic-data transfer
Federal Law No. 152-FZ of 2006Personal data protection
Federal Law No. 99-FZ of 2011Licensing of activities
Federal Law No. 242-FZ of 2014Regulation of medical devices
Government Resolution No. 479 of 2019State programme for gene technology development

These laws operate together rather than independently.

For example, a personalised gene-based treatment may involve medicinal-product registration, patient consent, genetic-data protection, clinical research approval and manufacturing controls.

4. Federal Law No. 323-FZ of 21 November 2011: Fundamental healthcare regulation

Federal Law No. 323-FZ – On the Fundamentals of Health Protection of Citizens in the Russian Federation.

This is one of the most important statutes governing future medicine.

It establishes general principles for medical treatment, research, informed consent, medical confidentiality and patient protection.

A. Article 2 – Basic healthcare concepts

Article 2 establishes important concepts relating to medical activities and healthcare.

It provides the legal foundation for understanding medical interventions, medical assistance and healthcare organisations.

B. Article 13 – Medical confidentiality

Article 13 protects medical confidentiality.

This is particularly important in future medicine because genetic and genomic information may reveal:

Hereditary disease risks.

Predispositions to particular illnesses.

Family relationships.

Genetic characteristics.

Information relevant to biological relatives.

Healthcare organisations must respect the statutory rules governing disclosure of confidential medical information.

C. Article 19 – Patient rights

Article 19 recognises patients' rights, including the right to medical assistance and information concerning their health.

In future medicine, patients should receive appropriate information about:

The proposed treatment.

Potential risks.

Expected benefits.

Alternative treatment methods.

Possible complications.

The experimental or innovative character of an intervention, where applicable.

D. Article 20 – Informed voluntary consent

Article 20 is especially significant.

Medical intervention generally requires informed voluntary consent, subject to statutory exceptions.

For emerging biotechnology treatments, consent should address the nature of the intervention and its material risks.

For example, a patient receiving experimental stem-cell treatment should be informed about:

The source of the cells.

The nature of the cellular intervention.

Potential immune reactions.

Possible tumour formation or other complications.

Available alternatives.

The uncertain nature of experimental results.

E. Article 37 – Organisation of medical assistance

Article 37 concerns the organisation and provision of medical assistance under applicable healthcare requirements.

Innovative treatments must comply with applicable medical procedures, clinical recommendations and healthcare standards.

F. Article 36.1 – Clinical approbation of methods

The statutory framework also recognises clinical approbation of new methods of prevention, diagnosis, treatment and rehabilitation.

This is important when medical organisations seek to introduce innovative methods into clinical practice.

Legal significance: Federal Law No. 323-FZ provides the general patient-protection framework within which specialised biotechnology legislation operates.

5. Federal Law No. 180-FZ of 23 June 2016: Biomedical cellular products

Major legislation

Federal Law No. 180-FZ, On Biomedical Cellular Products, is one of Russia's most important statutes for regenerative and future medicine.

It regulates the development, preclinical research, clinical investigation, examination, registration, production, quality control, distribution, use, storage and transportation of biomedical cellular products.

The law also regulates biological-material donation for manufacturing such products.

Consultant Plus+1

 

A. Meaning of biomedical cellular products

Biomedical cellular products are specialised products involving human cells and cellular technologies intended for medical purposes.

They are relevant to:

Regenerative medicine.

Stem-cell treatment.

Tissue restoration.

Cellular immunotherapy.

Treatment of certain degenerative conditions.

Repair of damaged biological tissues.

B. Article 3 – Principles of regulation

The legislation establishes principles governing the circulation of biomedical cellular products.

The regulatory approach emphasises:

Safety.

Quality.

Effectiveness.

Scientific justification.

Protection of patients and donors.

State supervision.

C. Articles 4–7 – Development and preclinical research

These provisions regulate important stages preceding clinical use.

They address matters such as:

Preparation of cell lines.

Development of cellular products.

Preclinical investigations.

Product specifications.

A biotechnology company cannot assume that a product is suitable for human use simply because preliminary laboratory experiments have produced favourable results.

Preclinical evidence must support the proposed clinical investigation.

D. Articles 8–25 – State registration

These provisions establish the registration and examination framework.

The registration process involves assessment of the product and relevant documentation.

The authorities consider matters such as:

Product composition.

Manufacturing methods.

Quality characteristics.

Safety evidence.

Scientific and clinical evidence.

Ethical considerations.

Registration is an important legal requirement for ordinary commercial circulation of products within the statutory regime.

E. Articles 14–18 – Ethical and scientific examination

These provisions are particularly important.

Biomedical cellular products require appropriate expert assessment, including ethical examination.

The regulatory system considers whether the potential benefits justify the possible risks.

This is important because cellular technologies can produce unpredictable biological effects.

F. Articles 28–30 – Clinical investigations

These provisions govern clinical investigations of biomedical cellular products.

Clinical investigations must comply with statutory requirements and receive the necessary authorisations.

The framework covers:

Organisation of clinical investigations.

Conduct of investigations.

International multicentre investigations.

Post-registration clinical investigations.

G. Articles 31–32 – Patient rights and insurance

These provisions protect individuals participating in clinical investigations.

Article 31 concerns patient rights, while Article 32 establishes mandatory insurance requirements relating to the life and health of clinical-investigation participants.

H. Article 32.1 – Individualised biomedical cellular products

This provision is particularly relevant to personalised future medicine.

It provides a specialised regulatory pathway for certain biomedical cellular products:

Manufactured specifically for an individual patient.

Produced directly within the medical organisation where they will be used.

Intended to fulfil an individual medical prescription.

This framework is supported by Government Resolutions Nos. 384 and 385 of 28 March 2024.

I. Articles 33–34 – Biological-material donation

These provisions regulate the collection of biological materials and donor rights.

The donor-protection framework is important for stem-cell and regenerative-medicine research.

J. Articles 35–39 – Manufacturing and medical use

These provisions regulate manufacturing, distribution-related requirements, labelling, storage, transportation and medical application.

K. Articles 41–42 – Safety monitoring

These provisions establish safety-monitoring and suspension mechanisms.

If a product presents serious safety concerns, the authorities may take appropriate regulatory action, including suspension of its application.

L. Articles 47–48 – Liability and compensation

Article 47 concerns legal responsibility for violations of the legislation.

Article 48 concerns compensation for harm caused to human life or health through the use of biomedical cellular products.

Legal significance: Federal Law No. 180-FZ is the central specialised legislative instrument for Russia's cellular and regenerative medicine sector.

Consultant Plus+1

 

6. Federal Law No. 61-FZ of 12 April 2010: Regulation of innovative medicinal products

Federal Law No. 61-FZ – On the Circulation of Medicinal Products.

This legislation is important for future medicines developed using biotechnology.

It governs medicinal products, including relevant biological and genetically engineered medicines.

Its application is particularly important for:

Gene-therapy medicinal products.

Recombinant proteins.

Monoclonal antibodies.

Recombinant vaccines.

Biotechnological medicines.

Innovative pharmaceutical formulations.

A. State registration

Medicinal products generally require state registration before ordinary commercial circulation.

The registration framework evaluates the product's quality, safety and efficacy.

B. Clinical trials

Clinical investigations must comply with the applicable requirements of pharmaceutical legislation.

For innovative medicines, the authorities examine whether sufficient scientific and clinical evidence exists to justify their use.

C. Manufacturing standards

Manufacturing must comply with applicable requirements concerning:

Pharmaceutical quality.

Manufacturing facilities.

Production processes.

Quality assurance.

Product testing.

Storage and distribution.

D. Pharmacovigilance

Post-registration monitoring is important because new biological medicines may produce adverse reactions that were not fully apparent during clinical trials.

Regulatory authorities may take action when new safety concerns emerge.

E. Gene-therapy medicines

Gene-therapy products that qualify as medicinal products are regulated through the applicable pharmaceutical framework.

The classification of the particular product is important. A cellular product regulated under Law No. 180-FZ should not automatically be treated as an ordinary medicinal product under Law No. 61-FZ.

Legal significance: Law No. 61-FZ provides the principal pharmaceutical regulatory framework for many advanced biological medicines, including relevant gene-based therapies.

7. Federal Law No. 86-FZ of 5 July 1996: Genetic engineering and future medicine

Federal Law No. 86-FZ – On State Regulation in the Field of Genetic Engineering Activities.

This law originally concentrated on the regulation of genetically engineered activities, particularly those involving genetically modified organisms.

It is also important for the development of Russia's genetic-data governance system.

A. Regulation of genetic engineering

Genetic engineering involves scientific methods for manipulating genetic material.

Relevant technologies include:

Recombinant DNA technology.

Gene transfer.

Genetic modification.

Molecular genetic techniques.

Genetic-data analysis.

B. Relationship with human gene therapy

A major legislative change occurred through Federal Law No. 643-FZ of 29 December 2022.

The amendments removed the previous express inclusion of gene diagnostics and gene therapy from the scope wording of Law No. 86-FZ.

Consequently, human gene therapy should not simply be assumed to be regulated as an ordinary genetically engineered organism activity.

Its applicable regulation depends on the nature of the technology and the relevant medical-product and healthcare legislation.

cis-legislation.com+1

 

C. Federal Law No. 43-FZ of 20 February 2026

Important 2026 development

Federal Law No. 43-FZ introduced further amendments to Federal Law No. 86-FZ.

It entered into force on 1 September 2026.

The amendments expressly address:

Genetic data of individuals.

The definition of human genetic information.

Population genetic and immunological research.

The transfer of human genetic data.

Conditions governing access to and disclosure of certain genetic datasets.

The legislation defines human genetic data by reference to nucleotide sequences and their chemical modifications obtained through molecular genetic research.

It also introduces a specific regulatory framework for population genetic and immunological studies involving groups of more than three individuals.

The transfer of genetic data obtained through such studies is subject to special statutory restrictions and exceptions.

cis-legislation.com+1

 

D. Importance for precision medicine

These amendments are significant for:

National genomic databases.

Population-genomics programmes.

Genetic disease research.

Pharmacogenomics.

Predictive genetic testing.

International scientific cooperation.

Cross-border transfer of genetic information.

For example, a research organisation conducting population-level genetic research must examine whether its proposed collection, storage, access arrangements and data transfers comply with the amended legislation.

Legal significance: Russia's genetic-data regime increasingly treats genetic information as a strategically important category of information requiring specialised governance.

8. Regulation of gene therapy and genome editing

Gene therapy is one of the most important components of future medicine.

It involves the introduction, modification, replacement or regulation of genetic material to prevent or treat disease.

Examples include:

Treatment of inherited genetic disorders.

Gene replacement.

Gene silencing.

Genetic modification of immune cells.

CRISPR-based genome editing.

Somatic-cell gene correction.

The CRISPR Craze Paints the Future of Genome Engineering | Health And Medicine

 

 

Frontiers | Gene Therapy Leaves a Vicious Cycle

 

 

Cardiotoxicity of T cell immunotherapies | Nature Reviews Cardiology

 

7

 

A. CRISPR-Cas9 technology

CRISPR-Cas9 is a genome-editing technology that enables targeted modification of DNA sequences.

Its possible medical applications include:

Correcting disease-associated mutations.

Developing cancer therapies.

Investigating hereditary diseases.

Modifying immune cells.

Developing experimental treatments for rare diseases.

Russian law does not establish one comprehensive CRISPR-specific statute.

Instead, the applicable framework depends on the nature of the intervention.

For example:

TechnologyPotential regulatory framework
Ex vivo modification of human cellsLaw No. 180-FZ, where the resulting product qualifies as a biomedical cellular product
In vivo gene therapy medicineLaw No. 61-FZ and applicable healthcare legislation
Genetic testingHealthcare, medical confidentiality and personal-data legislation
Research involving human participantsLaw No. 323-FZ and relevant clinical-research requirements
Genetic information transferLaw No. 86-FZ, as amended

B. Somatic gene editing

Somatic gene editing modifies cells of an individual without intentionally altering the genetic inheritance of future generations.

It may potentially be used to treat:

Cancer.

Genetic blood disorders.

Immunological disorders.

Certain inherited diseases.

Such treatment must satisfy applicable medical, product-registration, clinical-research and patient-protection requirements.

C. Germline genome editing

Germline editing involves changes to reproductive cells or embryos that may be transmitted to future generations.

This raises much more serious ethical and legal questions.

The legal analysis must distinguish between:

Research on embryos.

Reproductive medical interventions.

Clinical implantation.

Heritable genetic modification.

Russia does not have a single comprehensive statute specifically regulating every possible form of CRISPR germline editing.

It would therefore be inaccurate to treat all germline-editing activities as either generally authorised or comprehensively prohibited under one biotechnology law.

D. Ethical concerns

Important concerns include:

Unintended genetic changes.

Long-term hereditary consequences.

Lack of sufficient safety evidence.

Consent difficulties.

Discrimination based on genetic characteristics.

Intergenerational harm.

These concerns must be considered alongside the applicable constitutional and healthcare framework.

9. Stem-cell research and regenerative medicine

Human Bone Marrow Mesenchymal Stem Cells - Innoprot Cell Systems

 

 

Materials Science & Engineering Series Part 12: Biomaterials - Wasil Zafar

 

 

Bioprinting turns reliable alternative for testing new drugs

 

8

 

Regenerative medicine seeks to restore damaged tissues, cells and organs.

Russia regulates many relevant activities through Federal Law No. 180-FZ and associated government and Ministry of Health regulations.

A. Embryonic stem cells

Embryonic stem cells have the ability to differentiate into numerous cell types.

Their potential applications include:

Regeneration of damaged tissues.

Investigation of genetic disorders.

Developmental biology.

Experimental disease modelling.

Their use raises additional ethical questions concerning embryo status, biological-material donation and research consent.

B. Adult stem cells

Adult stem cells are obtained from developed tissues, such as bone marrow and other biological sources.

They are investigated for their potential application in:

Blood disorders.

Tissue repair.

Immunological conditions.

Regenerative treatment.

C. Induced pluripotent stem cells

Induced pluripotent stem cells are generated by reprogramming mature cells into a pluripotent state.

They have potential applications in:

Personalised disease modelling.

Drug development.

Genetic disease research.

Regenerative medicine.

Their legal treatment depends on the nature of the resulting product and its intended application.

D. Tissue engineering

Tissue engineering combines cells, biomaterials and engineering methods to develop biological structures.

Potential applications include:

Artificial skin.

Cartilage regeneration.

Bone reconstruction.

Organ-support technologies.

Laboratory-grown tissues.

Where an engineered product falls within the biomedical cellular product definition, Law No. 180-FZ becomes particularly relevant.

E. Individual-use cellular products: 2024 regulatory reforms

Russia introduced an important specialised framework through:

Government Resolution No. 384 of 28 March 2024.

Government Resolution No. 385 of 28 March 2024.

These rules became effective on 1 September 2024.

They establish procedures for certain individual-use biomedical cellular products manufactured directly in the medical organisation where they are administered.

The relevant expert evaluation is conducted through the designated scientific expert institution, and the Ministry of Health grants the required authorisation.

This framework is particularly important for personalised regenerative medicine.

regmed.ru+1

 

10. Personalised medicine and precision medicine regulation

Personalised medicine involves adapting medical prevention, diagnosis and treatment to the characteristics of an individual patient.

It uses information such as:

Genetic composition.

Molecular biomarkers.

Medical history.

Biological characteristics.

Pharmacological responses.

Clinical test results.

A. Pharmacogenomics

Pharmacogenomics examines how genetic differences influence a person's response to medicines.

For example, genetic variations may influence:

Drug metabolism.

Drug toxicity.

Treatment effectiveness.

Appropriate dosage.

Adverse drug reactions.

Its legal framework involves healthcare regulation, genetic-data protection and medicinal-product requirements.

B. Predictive genetic medicine

Predictive genetic testing identifies genetic variations associated with future disease risks.

Examples include testing for inherited cancer susceptibility and certain hereditary cardiovascular conditions.

The legal framework requires appropriate protection of patient information and compliance with applicable rules concerning medical diagnosis and genetic-data processing.

C. Personalised biotechnological medicines: Government Resolution No. 213 of 24 February 2025

Important personalised-medicine reform

Government Resolution No. 213 of 24 February 2025 introduced a specialised regulatory framework for certain biotechnological medicinal products.

It covers products:

Made for a specific individual patient.

Manufactured directly in the medical organisation where they will be used.

Intended for use pursuant to an individual medical prescription.

Containing compounds synthesised using results from genetic research of biological material obtained from that patient.

The regulation establishes requirements concerning manufacturing, examination, quality control, authorisation, application, storage, transportation and disposal.

It took effect on 25 February 2025 and is scheduled to remain in force until 25 February 2031.

ГАРАНТ

 

This development is important because it creates a specific legal route for a category of highly personalised biotechnological medicines.

It should be distinguished from the individual-use cellular-product framework under Article 32.1 of Law No. 180-FZ.

11. Artificial intelligence and future medical diagnosis

Artificial intelligence is increasingly relevant to Russian healthcare.

St Vincent's Hospital Sydney to deploy SNAC's AI diagnostic solutions | Healthcare IT News

 

 

healthcareitnews.com

Applications include:

Medical image analysis.

Early disease detection.

Predictive diagnostics.

Genomic data analysis.

Clinical decision support.

Drug discovery.

Personalised treatment planning.

A. Applicable legal framework

There is no single comprehensive Russian statute specifically governing every form of AI-based medical diagnosis and treatment.

The applicable framework may include:

Federal Law No. 323-FZ.

Federal Law No. 152-FZ on personal data.

Federal Law No. 242-FZ on medical devices.

Applicable technical regulations.

Medical-device registration requirements.

Medical confidentiality rules.

B. Medical-device classification

AI software may qualify as a medical device depending on its intended purpose and functionality.

Software used to diagnose disease or support medical decisions may therefore require regulatory assessment and, where applicable, registration.

C. Liability for AI-related medical errors

Important legal questions include:

Whether the medical organisation exercised appropriate professional care.

Whether the software was properly registered where registration was required.

Whether the manufacturer complied with applicable technical requirements.

Whether the doctor relied unreasonably on automated recommendations.

Whether the AI system caused or contributed to patient injury.

AI cannot automatically eliminate the responsibility of medical professionals or manufacturers.

12. Clinical trials and experimental future medicines

Clinical research is a central part of future medicine regulation.

Innovative medical products must undergo appropriate scientific and ethical evaluation before being introduced into ordinary medical practice.

A. Clinical-trial authorisation

Depending on the classification of the product, clinical research may be governed by:

Federal Law No. 61-FZ.

Federal Law No. 180-FZ.

Federal Law No. 323-FZ.

Applicable Ministry of Health regulations.

B. Ethical review

Ethical examination protects research participants against unjustified risks.

Important considerations include:

Scientific validity.

Patient selection.

Informed consent.

Risk-benefit assessment.

Privacy.

Protection of vulnerable participants.

Monitoring of adverse events.

C. Informed consent

Patients must receive appropriate information about the research and its possible consequences.

Consent must be voluntary and comply with the applicable statutory framework.

D. Insurance and compensation

Under Article 32 of Law No. 180-FZ, compulsory insurance requirements apply to participants in relevant biomedical cellular product clinical investigations.

The wider pharmaceutical clinical-trial regime also contains participant-protection and compensation provisions.

E. Post-trial monitoring

The regulatory responsibility does not necessarily end when a clinical investigation is completed.

Safety monitoring, reporting and regulatory supervision remain important after product registration.

13. Important judicial decisions and case laws

Russian judicial decisions specifically addressing future medicine, gene therapy and regenerative medicine remain relatively limited.

A significant distinction must be maintained between:

Judgments directly interpreting biotechnology legislation.

Healthcare licensing judgments relevant to innovative medical services.

General medical-liability judgments that may provide analogous principles.

The following documented case is particularly relevant.

Case 1. Institute of Human Stem Cells v. Roszdravnadzor

Important biotechnology-related case

Supreme Court of the Russian Federation, 13 June 2017, Case No. A40-58903/2016, No. 305-KG17-6103.

Facts of the case

The Public Joint-Stock Company Institute of Human Stem Cells held a medical activity licence issued on 14 March 2012.

The licence authorised medical activities involving high-technology medical assistance using cellular technologies.

Roszdravnadzor conducted an inspection and issued an enforcement order on 23 December 2015.

The authority required the organisation to bring its licence into conformity with the applicable licensing legislation.

The Institute challenged the enforcement order.

Procedural history

CourtDecision
Moscow Arbitration Court, 22 July 2016Rejected the Institute's claim
Ninth Arbitration Court of Appeal, 31 October 2016Reversed the first-instance decision and granted relief
Moscow District Arbitration Court, 21 February 2017Reversed the appellate judgment and restored the first-instance decision
Supreme Court, 13 June 2017Refused to refer the cassation complaint for consideration by the Economic Disputes Judicial Chamber

Legal issue

Whether an existing licence authorising medical activities involving cellular technologies had to be brought into conformity with the revised licensing requirements.

Decision

The Supreme Court found no sufficient grounds for referring the complaint for consideration by the Judicial Chamber.

The result was that the lower-court decision rejecting the Institute's challenge remained effective.

Legal principles and significance

The case demonstrates that:

Medical organisations providing cellular-technology services must comply with applicable licensing requirements.

Existing medical licences are not necessarily exempt from subsequent regulatory changes.

Regulatory authorities can require organisations to update their licences.

The use of innovative cellular technologies does not remove ordinary healthcare licensing obligations.

Relevance to future medicine

This case is important for organisations developing:

Stem-cell treatments.

Regenerative medicine.

Cellular therapies.

Innovative biomedical interventions.

However, an important qualification is necessary: this dispute arose before Federal Law No. 180-FZ became effective on 1 January 2017. It is therefore a relevant licensing precedent, not a judicial interpretation of the substantive provisions of Law No. 180-FZ.

Sudact

 

Case 2. Regulatory disputes concerning biomedical cellular products under Law No. 180-FZ

There is an important limitation in the available jurisprudence.

The Institute of Human Stem Cells case is sometimes presented as a direct precedent under Law No. 180-FZ. That description is historically incorrect because the dispute arose in 2015.

Law No. 180-FZ subsequently established the specialised regulatory framework.

Potential disputes under this law may concern:

Refusal of product registration.

Refusal of clinical-investigation authorisation.

Cancellation of registration.

Manufacturing licence violations.

Suspension of cellular-product use.

Donor consent.

Product contamination.

Adverse reactions.

Compensation for patient injuries.

Article 26 of Law No. 180-FZ specifically provides for challenging certain refusals concerning clinical-investigation authorisation and state registration.

Articles 47 and 48 address responsibility and compensation.

These provisions are important statutory foundations for future litigation, but they should not be confused with already-established judicial holdings.

Case 3. Disputes concerning genetic-data protection

The Russian legal framework governing genetic information has developed substantially.

The amendments introduced by Law No. 643-FZ of 2022 and Law No. 43-FZ of 2026 provide a statutory basis for disputes involving genetic-data collection and transfer.

Potential legal disputes include:

Unauthorised disclosure of genomic information.

Unlawful transfer of population-genetic datasets.

Improper processing of genetic information.

Violations of medical confidentiality.

Unauthorised access to genetic databases.

The applicable legislation includes Law No. 86-FZ, Law No. 152-FZ and the relevant healthcare confidentiality provisions.

These are important areas for future judicial development. They should not, however, be represented as settled case-law precedents without an identifiable judgment.

Case-law research conclusion

The publicly identifiable decisions reviewed for this subject do not establish a substantial body of Supreme Court jurisprudence specifically interpreting modern gene-editing, CRISPR or personalised regenerative-medicine regulation.

For academic work, the 2017 Supreme Court decision is a verifiable biotechnology-related licensing precedent. The remaining areas should be discussed through statutory interpretation rather than invented case citations.

14. Government programme for the development of gene technologies

Russia has also adopted policy measures supporting biotechnology and advanced medicine.

Government Resolution No. 479 of 22 April 2019

This resolution approved the State Scientific and Technical Programme for the Development of Gene Technologies in the Russian Federation for 2019–2027.

The programme promotes:

Genetic research.

Genome editing.

Molecular biology.

Gene therapy research.

Genetic diagnostics.

Development of scientific infrastructure.

Biotechnology innovation.

It is an important policy instrument supporting the development of future medicine.

However, a government development programme does not itself authorise an unregistered medical product to be marketed or administered outside the applicable legal requirements.

MDPI+1

 

2026 healthcare strategy implementation

The Government's implementation plan approved by Order No. 1693-r of 1 July 2026 also identifies the development of new medical and genetic technologies.

Its objectives include:

Pharmacogenetics.

Predictive genetics.

New preventive and diagnostic methods.

Personalised biological medicines.

Biomedical cellular products.

Tissue-engineering products.

Genetic editing technologies for medical applications.

The plan includes further implementation work extending into 2027 and 2030.

Consultant Plus+1

 

15. Regulation of biobanks and human biological materials

Biobanks are essential for future medicine because they preserve biological materials and associated information for scientific and medical research.

So, what’s a biobank actually for? - Eurac Research

 

 

eurac.edu

Examples of stored materials include:

Blood.

Tissue samples.

Stem cells.

DNA.

RNA.

Cellular lines.

Other human biological materials.

A. Applicable legislation

Relevant legal instruments include:

Federal Law No. 180-FZ.

Federal Law No. 323-FZ.

Federal Law No. 152-FZ.

Ministry of Health Order No. 842n of 13 April 2018, concerning biobank organisation and the storage of biological materials and cellular materials.

B. Legal responsibilities

Biobanks must address:

Lawful acquisition of biological material.

Appropriate donor consent.

Storage and preservation.

Traceability.

Confidentiality.

Access restrictions.

Lawful use in research.

Disposal of biological materials where required.

C. Genetic information and international transfer

The 2026 amendments to Law No. 86-FZ make genetic-data transfer particularly important.

A biobank dealing with population-genetic datasets must examine whether access, disclosure, transfer and international cooperation comply with the amended requirements.

16. Foreign investment and international cooperation in future medicine

Russia's future-medicine sector may involve international pharmaceutical companies, biotechnology businesses, universities and research institutions.

Relevant activities include:

Joint gene-therapy research.

International clinical trials.

Pharmaceutical manufacturing.

Genomic research partnerships.

Technology licensing.

Biobank cooperation.

A. Foreign investment

Foreign investment is subject to general Russian investment legislation and any applicable sector-specific restrictions.

Federal Law No. 57-FZ of 29 April 2008 concerning foreign investment in strategically important business entities may become relevant where the relevant entity and activity fall within its scope.

Not every biotechnology company is automatically subject to strategic-investment restrictions.

B. Cross-border genetic data

International research partnerships must also consider:

Federal Law No. 152-FZ.

Federal Law No. 86-FZ, as amended.

Medical confidentiality rules.

Applicable research-consent requirements.

The fact that a foreign university is participating in a research project does not automatically authorise unrestricted transfer of Russian genetic datasets.

C. International clinical trials

International multicentre research may be conducted subject to the relevant Russian clinical-investigation and regulatory requirements.

For biomedical cellular products, Article 30 of Law No. 180-FZ specifically addresses international multicentre and post-registration clinical investigations.

17. Regulatory authorities responsible for future medicine

Several Russian governmental bodies participate in the regulation of future medicine.

AuthorityPrincipal responsibilities
Ministry of HealthHealthcare policy, medical regulation and relevant authorisations
RoszdravnadzorHealthcare supervision, licensing and regulatory enforcement
RospotrebnadzorPublic health and sanitary-epidemiological supervision
Ministry of Science and Higher EducationScientific research and biotechnology development
Government of the Russian FederationNational policy and regulatory resolutions
Federal expert institutionsScientific and expert assessment of relevant medical products

Role of Roszdravnadzor

Roszdravnadzor has an important role in supervising medical organisations and regulated products.

Its responsibilities may involve:

Medical licensing.

Product-quality supervision.

Regulatory inspections.

Enforcement measures.

Safety monitoring.

Compliance with applicable healthcare legislation.

Role of the Ministry of Health

The Ministry of Health is particularly important for:

Clinical research authorisations.

Medical-product regulation.

Relevant registration decisions.

Individual-use biomedical cellular product authorisations.

Healthcare policy.

18. Liability for violations of future medicine legislation

Future medicine can create serious legal risks because biological interventions may produce consequences that are difficult to predict.

Russian law provides several potential forms of liability.

A. Civil liability

Civil liability may arise where an unlawful medical intervention or defective product causes injury.

Relevant provisions include:

Civil Code Article 1064 – General grounds of liability for causing harm.

Civil Code Article 1095 – Liability for harm caused by defects in goods, work or services.

Civil Code Article 1096 – Persons liable for harm caused by defects.

Federal Law No. 180-FZ, Article 48 – Compensation for harm resulting from biomedical cellular products.

B. Administrative liability

Administrative consequences may arise from:

Medical licensing violations.

Violations of sanitary requirements.

Improper medical-product circulation.

Unlawful personal-data processing.

Breaches of applicable regulatory requirements.

The Code of Administrative Offences contains relevant provisions, including Article 19.20 concerning certain activities conducted without the required special authorisation.

C. Criminal liability

Criminal liability may arise in serious cases.

Potentially relevant provisions include:

Criminal Code provisionSubject
Article 109Causing death by negligence
Article 118Causing serious harm to health by negligence
Article 238Providing services that do not meet safety requirements
Article 137Violation of privacy
Article 293Negligence by officials

The application of any provision depends on the particular facts and the legal elements of the offence.

For example, an adverse medical outcome does not automatically establish criminal negligence.

D. Professional responsibility

Medical professionals may also face professional and employment-related consequences for:

Treatment without appropriate consent.

Departure from applicable professional requirements.

Improper clinical documentation.

Unauthorised experimental treatment.

Failure to report serious adverse events.

19. Major legal challenges in regulating future medicine in Russia

Despite the development of specialised legislation, several important legal challenges remain.

A. Absence of a unified future-medicine statute

Russia regulates future medicine through multiple statutes.

This creates difficulties when one technology simultaneously involves:

Genetic modification.

Cellular products.

Biological materials.

Pharmaceutical manufacturing.

Personalised medical treatment.

A single technology may therefore require compliance with several legal regimes.

B. Uncertainty surrounding genome editing

CRISPR and other gene-editing technologies are developing rapidly.

The law must address:

Somatic genetic modification.

Germline editing.

Embryonic research.

Long-term biological consequences.

Clinical applications.

The absence of a comprehensive technology-specific framework creates uncertainty in some areas.

C. Protection of genetic privacy

Genetic information can reveal information about individuals and their biological relatives.

The 2026 amendments to Law No. 86-FZ strengthen the specialised legal framework for genetic-data transfer.

Nevertheless, practical questions remain concerning international scientific cooperation, access to databases and the protection of research participants.

D. Patient safety

Innovative treatments may cause:

Immune reactions.

Unexpected genetic changes.

Tumour development.

Organ damage.

Long-term adverse effects.

Regulatory authorities must therefore maintain effective safety-monitoring systems.

E. Commercialisation of experimental treatments

A major challenge is distinguishing legitimate experimental research from commercial medical services presented as scientifically proven treatments.

Medical organisations should not market an experimental intervention as an established cure without the necessary legal and scientific basis.

F. Access to innovative treatment

Advanced treatments can be expensive and may be available only in specialised institutions.

This creates questions about:

Equal access.

Public healthcare financing.

Regional healthcare disparities.

Treatment availability.

Reimbursement.

20. Important legislation and case-law reference table

The following table provides a useful reference for legal research and examination preparation.

Legal authorityMain relevance
Constitution, Article 20Right to life
Constitution, Article 21Human dignity
Constitution, Article 41Right to health protection
Federal Law No. 323-FZ (2011)Patient rights and healthcare
Federal Law No. 61-FZ (2010)Biological and innovative medicines
Federal Law No. 180-FZ (2016)Cellular and regenerative medicine
Federal Law No. 86-FZ (1996)Genetic engineering and genetic-data transfer
Federal Law No. 152-FZ (2006)Personal-data protection
Federal Law No. 43-FZ (2026)Amendments concerning human genetic data
Government Resolution No. 479 (2019)Gene-technology development programme
Government Resolutions Nos. 384 and 385 (2024)Individual-use cellular products
Government Resolution No. 213 (2025)Certain personalised biotechnological medicines
Government Order No. 1693-r (2026)Healthcare and genetic-technology implementation plan
Supreme Court, No. 305-KG17-6103 (2017)Cellular-technology medical licensing dispute

21. Future direction of Russian biotechnology law

Công nghệ gen đã giúp người Việt tốt hơn như thế nào?

 

 

From Petri Dish to Patient: The Rise of Organoids and 3D‑Printed Organs

 

 

iCharm – Shaping the Future of Personalized Medicine Through the Power of AI, Bioinformatics, Digital Technology, and Evidence-Based Medicine

 

12

 

Russia's future-medicine regulatory system is likely to develop in several directions.

Emerging technologyMain legal concern
CRISPR gene editingSafety, authorisation and ethical restrictions
Artificial organsProduct quality and medical-device regulation
Stem-cell therapiesRegistration, manufacturing and patient safety
Personalised medicinesIndividualised production and authorisation
Predictive genomicsGenetic privacy and informed consent
AI-based diagnosisMedical-device regulation and liability
BioprintingBiological-material and product regulation
Gene-based cancer treatmentsClinical trials and pharmaceutical regulation
Advanced biobanksDonor rights and genetic-data governance
Regenerative medicineLong-term safety and compensation

The 2026 amendments to the genetic-data framework and the government's healthcare technology development programme demonstrate the increasing importance of genetic information and personalised treatment in Russian regulatory policy.

22. Overall legal assessment

The Russian approach to future medicine can be understood through five principal regulatory pillars.

1. Genetic regulation

Federal Law No. 86-FZ and the 2026 amendments govern relevant genetic-engineering and genetic-data issues.

2. Cellular and regenerative medicine

Federal Law No. 180-FZ establishes the specialised framework for biomedical cellular products.

3. Pharmaceutical regulation

Federal Law No. 61-FZ governs relevant innovative medicinal products.

4. Patient protection

Federal Law No. 323-FZ protects informed consent, medical confidentiality and healthcare rights.

5. Judicial and regulatory accountability

Civil, administrative and criminal legislation provides mechanisms for addressing unlawful medical activities and patient injury.

23. Conclusion

Future medicine regulation in Russia represents an evolving combination of biotechnology legislation, pharmaceutical regulation, healthcare law, genetic-data protection and medical ethics.

Federal Law No. 180-FZ is particularly important for stem-cell research, cellular therapies and regenerative medicine. Federal Law No. 61-FZ provides the pharmaceutical framework for innovative biological and gene-based medicinal products. Federal Law No. 323-FZ protects patients through informed consent, medical confidentiality and general healthcare requirements.

Two significant developments deserve particular attention: Government Resolution No. 213 of 2025, which establishes a framework for certain personalised biotechnological medicines, and Federal Law No. 43-FZ of 2026, which strengthens the regulation of human genetic-data transfer.

The Supreme Court's 2017 Institute of Human Stem Cells decision demonstrates that innovative medical technologies remain subject to ordinary licensing and regulatory obligations.

Ultimately, Russia's legal approach seeks to promote biomedical innovation while ensuring scientific reliability, patient safety, ethical responsibility and state supervision. However, the absence of one comprehensive statute covering all emerging technologies remains a significant challenge.

24. Primary legal and academic sources for further research

Federal Law No. 180-FZ – On Biomedical Cellular Products.

Federal Law No. 86-FZ – On State Regulation in the Field of Genetic Engineering Activities.

Federal Law No. 643-FZ of 2022 – Genetic Engineering Amendments.

Federal Law No. 43-FZ of 2026 – Genetic Data Amendments.

Government Resolution No. 213 of 2025 – Personalised Biotechnological Medicines.

Russian Scientific Centre for Expert Evaluation of Medicinal Products – Individual-use Cellular Products.

Supreme Court of Russia – Case No. A40-58903/2016.

Almost 40 Years of Tissue Engineering in Russia: Where Are We Now?.

Transforming the Legal Regulation of Regenerative Medicine: Conflict of Laws and Resolution Mechanisms (2026).

Academic qualification: This is a research-oriented overview, not an exhaustive account of every implementing regulation. For litigation, clinical-trial applications or commercial product registration, the current consolidated Russian-language legislation and applicable technical requirements should be checked.

LawGratis provides pro bono legal aid and resources to empower communities. Join us in making justice reachable for everyone! Follow our community on Instagram, YouTube, Facebook, and LinkedIn.

LEAVE A COMMENT